Detalhe da pesquisa
1.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
N Engl J Med
; 389(23): 2162-2174, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38055253
2.
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.
Br J Clin Pharmacol
; 90(2): 568-581, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37872122
3.
Antibody-Drug Conjugates for Cancer Treatment.
Annu Rev Med
; 69: 191-207, 2018 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29414262
4.
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
Gynecol Oncol
; 147(2): 402-407, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28843653
5.
Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Breast Cancer Res Treat
; 124(1): 1-11, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20803067
6.
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
Invest New Drugs
; 28(3): 334-42, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19415181
7.
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
Med Oncol
; 26(2): 202-9, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19229667
8.
Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
Clin Cancer Res
; 13(2 Pt 1): 584-90, 2007 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17255281
9.
Advances in the management of epithelial ovarian cancer.
J Reprod Med
; 50(6): 426-38, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16050567
10.
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
J Clin Oncol
; 32(2): 68-75, 2014 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24323026
11.
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
J Clin Oncol
; 31(30): 3791-9, 2013 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24019545
12.
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
J Clin Oncol
; 31(2): 195-202, 2013 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23233719
13.
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.
Eur J Cancer
; 48(2): 253-62, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22033322
14.
Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
J Clin Oncol
; 29(13): 1750-6, 2011 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21444868
15.
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
J Clin Oncol
; 29(21): 2933-40, 2011 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21690471
16.
Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.
Pharmacoeconomics
; 28(7): 577-84, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20550223
17.
Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Semin Oncol
; 36 Suppl 3: S37-45, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19963099
18.
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Semin Oncol
; 36 Suppl 3: S26-36, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19963097
19.
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Cancer
; 115(16): 3651-60, 2009 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19526589
20.
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
J Clin Oncol
; 27(23): 3822-9, 2009 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19581539